ArticlePLoS computational biology2025
Modelling transmission thresholds and hypoendemic stability for onchocerciasis elimination.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Modelling anti-Ov16 seroprevalence for the control and elimination of onchocerciasis.Nature communications · 2026Article
- Public health impact of nuisance biting blackfly (Simulium damnosum s.l.) along the Asejire dam in Southwest, Nigeria.BMC public health · 2026Article
- The risk of onchocerciasis infection by human population movements between high and low transmission settings in Ghana.PLoS neglected tropical diseases · 2026Article
- Significant gap between Point participation and long‑term treatment adherence: An evaluation of ivermectin MDA in the Kwanware‑Ottou persistent onchocerciasis transmission focus, Wenchi, Ghana.PLoS neglected tropical diseases · 2026Article
- Modelling the effects of immigration on the re-introduction of onchocerciasis.Parasites & vectors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The World Health Organization (WHO) has proposed elimination of onchocerciasis transmission (EOT) in a third of endemic countries by 2030. This requires country-wide verification of EOT. Prior to the shift from morbidity control to EOT, interventions in Africa were mostly targeted at moderate- to high-transmission settings, where morbidity was most severe. Consequently, there remain numerous low transmission (hypoendemic) settings which have hitherto not received mass drug administration (MDA) with ivermectin. The WHO has prioritised the delineation of hypoendemic settings to ascertain treatment needs. However, the stability of transmission at such low levels remains poorly understood. We use the stochastic EPIONCHO-IBM transmission model to characterise the stability of transmission dynamics in hypoendemic settings and identify a range of threshold biting rates (TBRs, the annual vector biting rates below which transmission cannot be sustained). We show how TBRs are dependent on population size, inter-individual exposure heterogeneity and simulation time. In contrast with deterministic expectations, there is no fixed TBR; instead, transmission can persist between 70 and 300 bites/person/year. Using survivorship models on data generated from model simulations, we find that multiple vector biting rates can sustain hypoendemic prevalence for several decades. These findings challenge the assumption that hypoendemic foci would naturally fade out following treatment in nearby higher-endemicity regions. Our modelling suggests that, to achieve EOT, treatment should be extended to all areas where endogenous infection is identified, emphasising the need for improved diagnostic tools suitable for detecting low-prevalence infection and for strategies that allow safe treatment of communities where MDA would not be suitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.